Digital Agenda
The Society of Hematologic Oncology's Ninth Annual Meeting will be held on September 8-11, 2021 as a virtual event. The focus of the 3.5-day program is state-of-the-art approaches in the field of hematologic malignancies.
The virtual meeting offers participants:
- live-stream multi-track session broadcast with live lectures, debates, plenary sessions and more
- ability to engage with other virtual participants and presenters
- 'live', virtual poster session and ongoing access to the poster hall for viewing, discussions and collaborations
- access to the virtual exhibit hall for discussions, information and FREE give-aways
- on-demand recordings for 4-months following the annual meeting
- digital copy of speakers' slides, final program and abstract proceedings published in the official CLML journal supplement
- CME, MOC, NCCPA, CNE, and CE credits.
You may view the SOHO 2021 session line-up in the following Digital Agenda. Those that have registered may select the link to join the session directly. Note that all times in the program are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC -5).
Wednesday, September 8, 2021 | |||
---|---|---|---|
6:00 AM - 7:00 AM | E-Poster Session I | Go To Session | |
6:45 AM - 7:45 AM | MTP Session I: AMLSession Chair: Lucy Godley
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session II: ALLSession Chair: Wendy Stock
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session III: NHLSession Chair: Mark Roschewski
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session IV: NHLSession Chair: Philippe Armand
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session V: CMLSession Chair: Jerald Radich
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session VI: MPNSession Chair: Andreas Reiter
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session VII: MDSSession Chair: Guillermo Montalban-Bravo
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session VIII: MMSession Chair: Sagar Lonial Other Plasma Cell Disorders
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session IX: CLLSession Chair: William Wierda Case Studies in CLL
| Go To Session | |
6:45 AM - 7:45 AM | MTP Session X: CTSession Chair: Saul Priceman Cellular Therapies for Solid Tumors
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XI: AMLSession Chair: Tapan Kadia
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XII: ALLSession Chair: Partow Kebriaei
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XIII: NHLSession Chair: Jorge J. Castillo
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XIV: NHLSession Chair: Jeremy Abramson
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XV: CMLSession Chair: Jerry Radich
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XVI: MPNSession Chair: Andreas Reiter
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XVII: MDSSession Chair: Rami Komrokji
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XVIII: MMSession Chair: Suzanne Lenztsch Non-BCMA Immunotherapy in MM
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XIX: CLLSession Chair: Jennifer Woyach Relapsed and Refractory CLL
| Go To Session | |
8:00 AM - 9:00 AM | MTP Session XX: CTSession Chair: Marcela Maus Late Toxicities of Cellular Therapies
| Go To Session | |
9:15 AM - 9:25 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIAWelcome and Opening Remarks | Susan O'Brien | President, Society of Hematologic Oncology | Go To Session | |
9:25 AM - 9:43 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIAHyper CVAD in 2021: Lessons Learned and New Approaches | Elias Jabbour, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
9:43 AM - 10:01 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIAMRD in ALL: Techniques and Therapeutic Utility | Lori Muffly, MD | The University of Stanford, Stanford, California, USA | Go To Session | |
10:01 AM - 10:19 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIANovel CAR-T Constructs for ALL | Peggy Peihua Lu, MD, PhD | Hebei Yanda Lu Daopei Hospital, Hebei, China | Go To Session | |
10:19 AM - 10:37 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIAAsparaginase: Understanding and Overcoming Toxicities | Ibrahim T. Aldoss, MD | City of Hope Comprehensive Cancer Center, Duarte, California, USA | Go To Session | |
10:37 AM - 10:55 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIANovel approaches to T-Cell ALL | David T. Teachey, MD | Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA | Go To Session | |
10:55 AM - 11:10 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIADEBATE: Optimal Time for Blinatumomab: Is it Time for MRD? | Rachel Rau, MD | Baylor College of Medicine, Houston, Texas, USA | Go To Session | |
11:10 AM - 11:31 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIADEBATE: Optimal Time for CAR-T: Is it Time for MRD? | Rebecca A. Gardner, MD | Seattle Children's Hospital, Seattle, Washington, USA | Go To Session | |
11:31 AM - 11:41 AM | SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIAOral Abstract - ALL-031: The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia | Shawn Lee, MD | St. Jude Children's Research Hospital, Memphis, Tennessee, USA | Go To Session | |
11:41 AM - 12:41 PM | Industry Expert Session IContinued Treatment in AML: The Role of Onureg (azacitidine) tablets Farhad Ravandi-Kashani, MD | MD Anderson Cancer Center | Houston, TX, USA This activity is sponsored by Bristol Myers Squibb | Go To Session | |
11:41 AM - 12:41 PM | Industry Expert Session IIZYNLONTA™, the First-and-Only CD19-Targeted ADC, for the Treatment of Adults with R/R DLBCL After Two or More Lines of Systemic Therapy | Adolfo Enrique Diaz Duque, MD, MSc | UT Health San Antonio, Mays Cancer Center, San Antonio, Texas, USA This activity is sponsored by ADC Therapeutics | Go To Session | |
1:11 PM - 1:31 PM | PLENARY SESSION ISession Chair: Susan O'Brien Managing Patients Relapsed or Refractory to Targeted Therapy | Jennifer R. Brown, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA | Go To Session | |
1:31 PM - 1:49 PM | SESSION II: MYELODYSPLASTIC SYNDROMESNew Approaches for Lower Risk MDS | Uwe Platzbecker, MD | Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany | Go To Session | |
1:49 PM - 2:07 PM | SESSION II: MYELODYSPLASTIC SYNDROMESNew Immunotherapy Approaches for MDS | Uma Borate, MD, MS | Ohio State University James Cancer Hospital, Columbus, Ohio, USA | Go To Session | |
2:07 PM - 2:25 PM | SESSION II: MYELODYSPLASTIC SYNDROMESNED Inhibition | Lionel Adès, MD, PhD | Hôpital Saint-Louis, Paris, France | Go To Session | |
2:25 PM - 2:43 PM | SESSION II: MYELODYSPLASTIC SYNDROMESBCL-2 Inhibition in MDS | Andrew Wei, MBBS, PhD | Alfred Hospital and Monash University, Melbourne, Australia | Go To Session | |
2:43 PM - 3:01 PM | SESSION II: MYELODYSPLASTIC SYNDROMESTargeting p53 in MDS | David A. Sallman, MD | H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA | Go To Session | |
3:01 PM - 3:11 PM | SESSION II: MYELODYSPLASTIC SYNDROMESOral Abstract: MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia | Luis E. Aguirre, MD | | Go To Session | |
3:31 PM - 3:49 PM | SESSION III: ACUTE MYELOID LEUKEMIAIDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy | Courtney D. DiNardo, MD, MSCE | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
3:49 PM - 4:07 PM | SESSION III: ACUTE MYELOID LEUKEMIANPM1 Mutated AML: From Bench to Bedside | Brunangelo Falini, MD | University of Perugia, Perugia, Italy | Go To Session | |
4:07 PM - 4:25 PM | SESSION III: ACUTE MYELOID LEUKEMIAFLT3 mutated AML: Moving Towards Cure | Alexander E. Perl, MD | University of Pennsylvania, Philadelphia, Pennsylvania, USA | Go To Session | |
4:25 PM - 4:43 PM | SESSION III: ACUTE MYELOID LEUKEMIAAntibody-Based Therapy in AML: Immunotoxins and Bi-specifics | Amir Fathi, MD | Massachusetts General Hospital, Boston, Massachusetts, USA | Go To Session | |
4:43 PM - 5:01 PM | SESSION III: ACUTE MYELOID LEUKEMIATP53 Mutated AML: New Horizons | Naval Daver, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
5:01 PM - 5:16 PM | SESSION III: ACUTE MYELOID LEUKEMIADEBATE: Is Maintenance Therapy in AML Necessary? YES | Farhad Ravandi, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
5:16 PM - 5:37 PM | SESSION III: ACUTE MYELOID LEUKEMIADEBATE: Is Maintenance Therapy in AML Necessary? NO | Jeffrey E. Lancet, MD | H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA | Go To Session | |
5:37 PM - 5:55 PM | SESSION III: ACUTE MYELOID LEUKEMIAMeasurable Residual Disease in AML | Jacqueline Cloos, PhD | Amsterdam UMC, Amsterdam, The Netherlands | Go To Session | |
5:55 PM - 6:05 PM | SESSION III: ACUTE MYELOID LEUKEMIAOral Abstract - AML-024: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia | Curtis Lachowiez, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
6:05 PM - 6:15 PM | SESSION III: ACUTE MYELOID LEUKEMIAOral Abstract - AML-345: Algorithmic Diagnostic Approach and Spectrum of Hematological Malignancies in Patients with Germline Predisposition Syndromes | Alejandro Ferrer, PhD | Mayo Clinic Rochester, Rochester, Minnesota, USA | Go To Session | |
6:15 PM - 6:30 PM | Poster and Industry Awards Session | Go To Session | |
6:30 PM - 7:30 PM | E-Poster Session II | Go To Session | |
8:15 PM - 9:45 PM | INDEPENDENT SATELLITE SYMPOSIUM IIExploring New Approaches for Treating Patients with Cytopenic Myelofibrosis John Mascarenhas, MD | Icahn School of Medicine at Mount Sinai, New York, New York, USA This CME activity is provided by Medscape. This activity is supported by an educational grant from CTI BioPharma Corp. | Go To Session | |
8:15 PM - 9:45 PM | INDEPENDENT SATELLITE SYMPOSIUM IIIData + Perspectives: Clinical Investigators Discuss the Current and Future Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes Moderator: Neil Love, MD | Research To Practice | Miami, Florida, USA This CME activity is provided by Research To Practice. This activity is supported by educational grants from Abbvie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo, Genentech, a member of the Roche Group, Gilead Sciences Inc and Jazz Pharmaceuticals Inc. | Go To Session | |
Thursday, September 9, 2021 | |||
6:15 AM - 7:45 AM | INDEPENDENT SATELLITE SYMPOSIUM IVSeizing the Day’ with BTK Inhibitors in CLL Co-Chair and Moderator, Nicole Lamanna, MD | Herbert Irving Comprehensive Cancer Center, New York, New York, USA This educational live symposium is accredited by Medical Learning Institute, Inc. for CME/MOC. | Go To Session | |
6:45 AM - 7:45 AM | BREAKFAST WITH THE EXPERT IHow I Use MRD: European and American Perspectives | Othman Al-Sawaf, MD | University Hospital of Cologne, Cologne, Germany How I Use MRD: European and American Perspectives | Matthew S. Davids, MD, MMSc | Dana-Farber Cancer Institute, Boston, Massachusetts, USA | Go To Session | |
8:00 AM - 8:18 AM | SESSION IV: MYELOPROLIFERATIVE NEOPLASMSSimple Guideline to Systemic Mastocytosis in 2021 | Jason R. Gotlib, MD, MS | Stanford University, Stanford, California, USA | Go To Session | |
8:18 AM - 8:36 AM | SESSION IV: MYELOPROLIFERATIVE NEOPLASMSPolycythemia Vera: Is it Time to Rethink Treatment? | Francesco Passamonti, MD | University of Insubria, Varese, Italy | Go To Session | |
8:36 AM - 8:54 AM | SESSION IV: MYELOPROLIFERATIVE NEOPLASMSEvolution in Prognostication in Myelofibrosis: From IPSS and DIPSS to MIPSS-70 and MYSEC-PM | Laura C. Michaelis, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA | Go To Session | |
8:54 AM - 9:12 AM | SESSION IV: MYELOPROLIFERATIVE NEOPLASMSAccelerated Phase of MPN: What Is It and What to Do About It | Olatoyosi Sobulo Odenike, MD | The University of Chicago Medicine, Chicago, Illinois, USA | Go To Session | |
9:12 AM - 9:30 AM | SESSION IV: MYELOPROLIFERATIVE NEOPLASMSPotential New Therapeutic Approaches for Myelofibrosis | Srdan Verstovsek, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
9:30 AM - 9:40 AM | SESSION IV: MYELOPROLIFERATIVE NEOPLASMSOral Abstract: MPN-133: Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the REVEAL Prospective, Observational Study | Carole B. Miller, MD | Ascension Saint Agnes Hospital, Baltimore, Maryland, USA | Go To Session | |
10:10 AM - 10:28 AM | SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIAMolecular and Microenvironmental Basis of Immunodysfunction in CLL | Silvia Deaglio, MD, PhD | University of Turin, Turin, Italy | Go To Session | |
10:28 AM - 10:46 AM | SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIASpectrum/Management of Infections in Patients with CLL | Carsten U. Niemann, MD, PhD | Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark | Go To Session | |
10:46 AM - 11:01 AM | SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIADEBATE: Old Prognostic Markers Still Have a Role in CLL Management | Inhye Ahn, MD | National Institutes of Health Clinical Center, Bethesda, Maryland, USA | Go To Session | |
11:01 AM - 11:22 AM | SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIADEBATE: Old Prognostic Markers Do Not Have a Role in CLL Management | Steven Coutre, MD | Stanford University School of Medicine, Stanford, California, USA | Go To Session | |
11:22 AM - 11:40 AM | SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIAApproaches to Therapy of Richter Syndrome | Davide Rossi, MD, PhD | Institute of Southern Switzerland, Bellinzona, Switzerland | Go To Session | |
11:40 AM - 11:58 AM | SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIANew Targetable Pathways | Alexey V. Danilov, MD, PhD | City of Hope National Medical Center, Duarte, California, USA | Go To Session | |
11:58 AM - 12:08 PM | SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIAOral Abstract - CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study | Catherine C. Coombs, MD | The University of North Carolina Cancer Center, Chapel Hill, North Carolina, USA | Go To Session | |
12:08 PM - 1:08 PM | Industry Expert Session IIIClinical Cases in Polycythemia Vera: When to Intervene With Jakafi® (rollatini) | Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea | David Rizzieri, MD | Duke University Medical Center This activity is sponsored by Incyte | Go To Session | |
12:08 PM - 1:08 PM | Industry Expert Session IVDiscover the Role of Two Immunotherapies in Myeloma Treatment William Velasquez, MD | Memorial Hermann | Houston, Texas, USA This activity is sponsored by Bristol Myers Squibb | Go To Session | |
1:38 PM - 1:58 PM | PLENARY SESSION IISession Chair: Hagop Kantarjian How I Treat PV Before and After Fibrotic Transformation | Ayalew Tefferi, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA | Go To Session | |
1:58 PM - 2:16 PM | SESSION VI: CHRONIC MYELOID LEUKEMIAState of the Art in CML: Update | Andreas Hochhaus, MD | University Medical Center Jena, Jena, Germany | Go To Session | |
2:16 PM - 2:34 PM | SESSION VI: CHRONIC MYELOID LEUKEMIACML and Pregnancy | Elisabetta Abruzzese, MD, PhD | S.Eugenio University Hospital, Rome, Italy | Go To Session | |
2:28 PM - 3:38 PM | SESSION VI: CHRONIC MYELOID LEUKEMIAOral Abstract - CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON) | Jorge Cortés, MD | Georgia Cancer Center at Augusta University, Augusta, Georgia, USA | Go To Session | |
2:34 PM - 2:52 PM | SESSION VI: CHRONIC MYELOID LEUKEMIAUpdate on TFR | Ehab L. Atallah, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA | Go To Session | |
2:52 PM - 3:10 PM | SESSION VI: CHRONIC MYELOID LEUKEMIAManaging TKI Resistance: New Options | Delphine Rea, MD, PhD | Hôpital Saint Louis, Paris, France | Go To Session | |
3:10 PM - 3:28 PM | SESSION VI: CHRONIC MYELOID LEUKEMIACase Study: Managing Cytopenias on TKI Therapy | Jane F. Apperley, MBChB, MD, FRCP, FRCPath | Hammersmith Hospital London Imperial College, London, United Kingdom | Go To Session | |
4:08 PM - 4:26 PM | SESSION VII: MULTIPLE MYELOMAFrontline Therapy for Amylodosis: Response Assessments | Angela Dispenzieri, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA | Go To Session | |
4:26 PM - 4:44 PM | SESSION VII: MULTIPLE MYELOMASalvage Therapy for Amyloidosis: Agents and Anti-Fibril Therapy | Suzanne Lentzsch, MD, PhD | Columbia University and at New York Presbyterian Hospital, New York, USA | Go To Session | |
4:44 PM - 5:02 PM | SESSION VII: MULTIPLE MYELOMAFrontline Therapy in TE NDMM: Pros and Con's; Quads, Early Transplant, Just Revlimid for Maintenance? | Amrita Y. Krishnan, MD, FACP | City of Hope National Medical Center, Duarte, California, USA | Go To Session | |
5:02 PM - 5:20 PM | SESSION VII: MULTIPLE MYELOMASequencing Treatment for Early Relapse: Which Triplets and When? | Maria-Victoria Mateos, MD, PhD | University Hospital of Salamanca, Spain | Go To Session | |
5:20 PM - 5:38 PM | SESSION VII: MULTIPLE MYELOMATreatment of Triple Class Refractory Myeloma: Novel Agents | Robert Z. Orlowski, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
5:38 PM - 5:56 PM | SESSION VII: MULTIPLE MYELOMANovel BCMA Targeted ADCs, Bispecific and Trispecific Antibodies | Saad Z. Usmani, MD, FACP | Levine Cancer Institute, Charlotte, North Carolina, USA | Go To Session | |
5:56 PM - 6:14 PM | SESSION VII: MULTIPLE MYELOMABCMA Directed CAR T-Cells: Early Results and Future Directions | Jesus G. Berdeja, MD | Sarah Cannon Cancer Institute, Nashville, Tennessee, USA | Go To Session | |
6:14 PM - 6:24 PM | SESSION VII: MULTIPLE MYELOMAOral Abstract - MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) | Saad Z. Usmani, MD, FACP | Levine Cancer Institute, Charlotte, North Carolina, USA | Go To Session | |
6:24 PM - 7:24 PM | INDUSTRY EXPERT SESSION VIConsiderations for Tailoring Treatment for First-Line and Relapsed/Refractory Follicular Lymphoma | Charles Farber, MD, PhD | Atlantic Medical Group, Morristown, New Jersey, USA This activity is sponsored by Genentech | Go To Session | |
6:24 PM - 7:24 PM | Industry Expert Session VA Case-based Presentation on Improving Outcomes in Patients With Newly-Diagnosed Secondary AML James McCloskey, MD | Chief of Leukemia | John Theurer Cancer Center | Hackensack University Medical Center, Hackensack, NJ This activity is sponsored by Jazz Pharmaceuticals | Go To Session | |
7:24 PM - 8:54 PM | INDEPENDENT SATELLITE SYMPOSIUM VPersonalizing Care for Patients with Low- to High-Risk MDS: Applying the Science to Real-World Case Scenarios Chair: Guillermo Garcia-Manero, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by an educational grant from Bristol Myers Squibb. | Go To Session | |
7:24 PM - 8:54 PM | INDEPENDENT SATELLITE SYMPOSIUM VIMedical Crossfire®: How Are We Meeting the Needs of Patients With CLL Across Lines of Care? Chair: William G. Wierda, MD, PhD , The University of Texas MD Anderson Cancer Center, Houston, Texas, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Genentech, Lilly and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc. | Go To Session | |
Friday, September 10, 2021 | |||
6:15 AM - 7:45 AM | INDEPENDENT SATELLITE SYMPOSIUM VIIRegimen Choice and Newly Approved Agents in Relapsed/Refractory Multiple Myeloma Chair: Sagar Lonial, MD, FACP | Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
For more information and to register for this ISS, go to https://bioascend.com/featured-activities/sohomm2021/ | Go To Session | |
6:30 AM - 7:45 AM | INDEPENDENT SATELLITE SYMPOSIUM VII AUnderstanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics Co-Chair & Moderator, Srdan Verstovsek, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA This educational live symposium is accredited by Medical Learning Institute, Inc. for CME/MOC. | Go To Session | |
8:00 AM - 8:18 AM | SESSION VIII: HODGKIN LYMPHOMAIntegrating Novel Agents into the Treatment of Classic Hodgkin Lymphoma | Ann Lacasce, MD, MMSc | Dana Farber Cancer Institute, Boston, Massachusetts, USA | Go To Session | |
8:18 AM - 8:36 AM | SESSION VIII: HODGKIN LYMPHOMATreatment Strategies in Nodular Lymphocyte Predominant Hodgkin Lymphoma | Ranjana H. Advani, MD | Stanford University Medical Center, Stanford, California, USA | Go To Session | |
8:36 AM - 8:54 AM | SESSION IX: T-CELL LYMPHOMANew Pathways and New Targets in PTCL | Ryan A. Wilcox, MD, PhD | University of Michigan, Ann Arbor, Michigan, USA | Go To Session | |
8:54 AM - 9:12 AM | SESSION IX: T-CELL LYMPHOMAMoving Beyond BV-CHP in PTCL | Neha Mehta-Shah, MD | Washington University School of Medicine, St. Louis, Missouri, USA | Go To Session | |
9:12 AM - 9:30 AM | SESSION IX: T-CELL LYMPHOMATreatment of Advanced CTCL in 2021 | Lauren C. Pinter-Brown, MD | UCI Health, Chao Family Comprehensive Cancer Center, Orange, California, USA | Go To Session | |
9:30 AM - 9:48 AM | SESSION IX: T-CELL LYMPHOMAImmunotherapy Approaches in T-Cell Lymphoma | Maksim Mamonkin, PhD | Baylor College of Medicine, Houston, Texas, USA | Go To Session | |
9:48 AM - 10:06 AM | SESSION IX: T-CELL LYMPHOMADisparities in Treatment in Patients with T-Cell Lymphoma | Mary Jo Lechowicz, MD | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA | Go To Session | |
10:06 AM - 10:16 AM | SESSION IX: T-CELL LYMPHOMAOral Abstract - TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma | Swaminathan P. Iyer, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
10:46 AM - 11:04 AM | SESSION X: INDOLENT B-CELL LYMPHOMAMolecular Pathogenesis of Follicular Lymphoma and Its Relevance to Clinical Practice | Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD | Barts Cancer Institute, London, United Kingdom | Go To Session | |
11:04 AM - 11:22 AM | SESSION X: INDOLENT B-CELL LYMPHOMASequencing Therapy in Follicular Lymphoma | Peter Martin, MD | Weill Medical College of Cornell University, New York, New York, USA | Go To Session | |
11:22 AM - 11:40 AM | SESSION X: INDOLENT B-CELL LYMPHOMANovel Therapies in Indolent Lymphoma | Loretta Nastoupil, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
11:40 AM - 11:58 AM | SESSION X: INDOLENT B-CELL LYMPHOMACar T-Cell Therapy in Indolent Lymphoma | Caron A. Jacobson, MD, MMSc | Dana-Farber Cancer Institute, Boston, Massachusetts, USA | Go To Session | |
11:58 AM - 12:08 PM | SESSION X: INDOLENT B-CELL LYMPHOMAOral Abstract - IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia | Jithma Abeykoon, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA | Go To Session | |
12:08 PM - 1:08 PM | INDUSTRY EXPERT SESSION VIITreatment for CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma) and Waldenstroms Macroglobulinemia (WM | Moshe Y. Levy | Baylor University Medical Center This activity is sponsored by Janssen Biotech & Pharmacyclics, LLC | Go To Session | |
12:08 PM - 1:08 PM | Industry Expert Session VIIIA Treatment Option for Patients with Myelodysplastic Syndromes Thomas William LeBlanc, MD | Duke University School of Medicine | Durham, North Carolina, USA This activity is sponsored by Bristol Myers Squibb | Go To Session | |
1:38 PM - 1:58 PM | PLENARY SESSION IIISession Chair: Moshe Talpaz From Biology to Therapy: Progress in Hodgkin Lymphoma | Stephen M. Ansell, MD, PhD | Mayo Clinic Rochester, Rochester, Minnesota, USA | Go To Session | |
1:58 PM - 2:16 PM | SESSION XI: AGGRESSIVE B-CELL LYMPHOMADissecting the Biology of DLBCL: How Close Are We to a Clinically Validated Molecular Platform? | Georg Lenz, MD | University Hospital Münster, Münster, Germany | Go To Session | |
2:16 PM - 2:34 PM | SESSION XI: AGGRESSIVE B-CELL LYMPHOMAInnovative Approaches in Untreated DLBCL | Jason R. Westin, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
2:34 PM - 2:52 PM | SESSION XI: AGGRESSIVE B-CELL LYMPHOMASequencing Therapies in Transplant-Ineligible DLBCL | Laurie H. Sehn, MD, MPH | BC Cancer, Vancouver, Canada | Go To Session | |
2:52 PM - 3:10 PM | SESSION XI: AGGRESSIVE B-CELL LYMPHOMAThe Next Wave of Novel Agents in Aggressive B-Cell Lymphoma | Gilles Salles, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA | Go To Session | |
3:10 PM - 3:28 PM | SESSION XI: AGGRESSIVE B-CELL LYMPHOMAUpdate on Primary Mediastinal B-Cell Lymphoma | Kieron M. Dunleavy, MD | Georgetown University, Washington DC, USA | Go To Session | |
3:28 PM - 3:46 PM | SESSION XI: AGGRESSIVE B-CELL LYMPHOMAHigh Grade B-Cell Lymphoma : Double/Triple Hit and NOS | Andrew Davies, MD | University of Southampton, Southampton, United Kingdom | Go To Session | |
3:46 PM - 3:56 PM | SESSION XI: AGGRESSIVE B-CELL LYMPHOMAOral Abstract - ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Brad S. Kahl, MD | Washington University Medical School, St. Louis, Missouri, USA | Go To Session | |
3:56 PM - 4:06 PM | SESSION XI: AGGRESSIVE B-CELL LYMPHOMAOral Abstract- ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts) | Cyrus Khan, MD | Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA | Go To Session | |
4:36 PM - 4:54 PM | SESSION XII: MANTLE CELL LYMPHOMADissecting the Biology of Mantle Cell Lymphoma: What is Clinically Relevant | Thomas Witzig, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA | Go To Session | |
4:54 PM - 5:12 PM | SESSION XII: MANTLE CELL LYMPHOMATailoring Upfront Therapy in Mantle Cell Lymphoma | Brad S. Kahl, MD | Washington University Medical School, St. Louis, Missouri, USA | Go To Session | |
5:12 PM - 5:30 PM | SESSION XII: MANTLE CELL LYMPHOMANovel Treatment Approaches in Relapsed/Refractory MCL | Kami J. Maddocks, MD | Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA | Go To Session | |
5:30 PM - 5:48 PM | SESSION XII: MANTLE CELL LYMPHOMACAR T-Cell Therapy in Mantle Cell Lymphoma | Michael Wang, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
5:48 PM - 6:48 PM | Industry Expert Session IXMonjuvi (Tafasitamab-Cxix) For Use As Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide | Ruemu Ejedafeta Birhiray, MD | Hematology-Oncology of Indiana This activity is sponsored by Incyte and MorphoSys | Go To Session | |
6:48 PM - 7:48 PM | Industry Expert Session XPOLIVY+BR: Advance the Possibilities in R/R DLBCL, NOS, After at Least 2 Prior Therapies John R. Pawloski, MD, PHD | Program Director, Cellular Therapy | Tampa General Hospital, Tampa, Florida, USA This activity is sponsored by Genentech | Go To Session | |
7:48 PM - 9:18 PM | INDEPENDENT SATELLITE SYMPOSIUM VIIINext-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA Sagar Lonial, MD | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA This CME activity is provided by Clinical Care Options, LLC. This activity is supported by an educational grant from GlaxoSmithKline. | Go To Session | |
7:48 PM - 9:18 PM | INDEPENDENT SATELLITE SYMPOSIUM VMedical Crossfire®: How Are We Integrating New Treatment Strategies into the Care of Our B-Cell Lymphoma Patients? Philippe Armand, MD, PhD | Dana-Farber Cancer Institute | Boston, Massachusetts, USA This CME activity is provided by Physicians’ Education Resource, LLC. | Go To Session | |
Saturday, September 11, 2021 | |||
6:15 AM - 7:45 AM | INDEPENDENT SATELLITE SYMPOSIUM XCAR T Cell Therapy in Lymphoma and Myeloma in Clinical Practice Christopher Flowers, MD | UT MD Anderson Cancer Center | Houston, Texas, USA This activity is supported by independent educational grants from Bristol-Myers Squibb and Legend Biotech USA Inc. For more information and to register for this ISS, go to https://bioascend.rievent.com/a/RCOMAF.” | Go To Session | |
6:45 AM - 7:45 AM | BREAKFAST WITH THE EXPERT IICell Therapy for Myeloma: When, Where, and What Type | Sergio Giralt, MD | Memorial Sloan-Kettering Cancer Center, New York, New York, USA | Go To Session | |
8:00 AM - 8:18 AM | SESSION XIII: CELLULAR THERAPYWelcome and Opening Remarks | Melody Smith, MD, MS | Memorial Sloan-Kettering Cancer Center, New York, New York, USA | Go To Session | |
8:18 AM - 8:36 AM | SESSION XIII: CELLULAR THERAPYCytotoxic T Lymphocyte Therapy for Viral Infection | Amanda L. Olson, MD | The University of Texas at MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
8:36 AM - 8:54 AM | SESSION XIII: CELLULAR THERAPYNYESO Targeted TCRs | Adam J. Schoenfeld, MD | Memorial Sloan-Kettering Cancer Center, New York, New York, USA | Go To Session | |
8:54 AM - 9:12 AM | SESSION XIII: CELLULAR THERAPYCAR T for Pediatric ALL: What's Next? | Stephan Grupp, MD, PhD | University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA | Go To Session | |
9:12 AM - 9:22 AM | SESSION XIII: CELLULAR THERAPYOral Abstract - CT-080: ATumor-Agnostic TCR-Mimic CAR-T cell Specific for NDC80 Targets Multiple Hematological Malignancies | Martin G. Klatt, MD | Memorial Sloan-Kettering Cancer Center, New York, New York, USA | Go To Session | |
9:52 AM - 10:02 PM | SESSION XIV: NEXT QUESTIONSSession Chairs: Susan O'Brien and Hagop Kantarjian
| Go To Session | |
10:02 AM - 10:12 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Acute Myeloid Leukemia | Hagop Kantarjian, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
10:12 AM - 10:22 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Cellular Therapy | Marcela V. Maus,MD,PhD | Massachusetts General Hospital, Boston, Massachusetts, USA | Go To Session | |
10:22 AM - 10:32 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Chronic Lymphocytic Leukemia | Susan O'Brien, MD | UCI Health Chao Family Comprehensive Cancer Center, Orange, California, USA | Go To Session | |
10:42 AM - 10:52 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Chronic Myeloid Leukemia | Jorge Cortés, MD | Georgia Cancer Center at Augusta University, Augusta, Georgia, USA | Go To Session | |
10:52 AM - 11:02 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Aggressive B-Cell Lymphoma | Grzegorz S. Nowakowski, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA | Go To Session | |
11:02 AM - 11:12 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Indolent B-Cell Lymphoma | Judith Trotman, MBChB, FRACP, FRCPA | Concord Repatriation General Hospital, Sydney, Australia | Go To Session | |
11:12 AM - 11:22 AM | SESSION XIV: NEXT QUESTIONSNext Questions: T-Cell Lymphoma | Barbara Pro, MD | Robert H Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA | Go To Session | |
11:22 AM - 11:32 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Mantle Cell Lymphoma | Martin Dreyling, MD, PhD | University of Munich, Munich, Germany | Go To Session | |
11:32 AM - 11:42 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Hodgkin Lymphoma | Craig H. Moskowitz, MD | University of Miami Health System, Miami, Florida, USA | Go To Session | |
11:42 AM - 11:52 AM | SESSION XIV: NEXT QUESTIONSNext Questions: Multiple Myeloma | Ola C. Landgren, MD, PhD | University of Miami Health System, Miami, Florida, USA | Go To Session | |
11:52 AM - 12:02 PM | SESSION XIV: NEXT QUESTIONSNext Questions: Myelodysplastic Syndromes | Guillermo Garcia-Manero, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
12:02 PM - 12:12 PM | SESSION XIV: NEXT QUESTIONSNext Questions: Myeloproliferative Neoplasms | Srdan Verstovsek, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Go To Session | |
12:30 PM | On-Demand Industry Expert Session IBLENREP belantamab mafodotin-blmf for injection 100mg Rafat Abonour, MD, Indianapolis, IN, USA This activity is sponsored by GlaxoSmithKline | Go To Session | |
12:30 PM | On-Demand Industry Expert Session IIBLENREP REMS: Real World Implementation and Best Practices Cristina Gasparetto, MD, Associate Professor of Medicine, Durham, North Carolina, USA Mark Newman, OD, MS, Optix Eyecare Center, Durham, North Carolina, USA This activity is sponsored by GlaxoSmithKline | Go To Session | |
12:30 PM | On-Demand Industry Expert Session IIIAYVAKIT: The ONLY Targeted Therapy for Advanced Systemic Mastocytosis Designed for Potent and Selective Inhibition of KIT D816V Andrew Kuykendall, MD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA This activity is sponsored by Blueprint Medicines Corporation | Go To Session | |
12:30 PM | On-Demand Industry Satellite Symposia INavigating Treatment Options for CML Across the Disease Continuum: An Expert Case- Based Discussion Chair: Elias Jabbour | MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by an educational grant from Novartis. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21cml | Go To Session | |
12:30 PM | On-Demand Industry Satellite Symposia IIAdvances in MF and PV: Individualizing Care Based on Patient- and Disease-Specific Factors Chair: Srdan Verstovsek, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Bristol Myers Squibb, Incyte Corporation, Protagonist Therapeutics, SDP Oncology. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21mpn | Go To Session | |
12:30 PM | On-Demand Industry Satellite Symposia IIIManaging Multiple Myeloma from Newly Diagnosed to Relapsed/Refractory Settings: An Expert Case-Based Discussion Chair: Saad Z. Usmani, MD, MBA, FACP | Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Sanofi Genzyme, Karyopharm Therapeutics, Oncopeptides. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21mm | Go To Session | |
12:30 PM | On-Demand Industry Satellite Symposia IVHow Can We Be More Strategic in Treatment Planning for Patients with ALL? Chair: Elias Jabbour, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Amgen, Inc and Takeda Oncology. | Go To Session | |
12:30 PM | On-Demand Industry Satellite Symposia VData + Perspectives: Clinical Investigators Discuss the Current and Future Management of Patients with Chronic Lymphocytic Leukemia Faculty: Jeff Sharman, MD | Willamette Valley Cancer Institute and Research Center | Eugene, Oregon, USA This CME activity is provided by Research To Practice. This activity is supported by an educational grant from Bristol Myers Squibb | Go To Session | |
12:30 PM | On-Demand Industry Satellite Symposia VIData + Perspectives: Clinical Investigators Discuss the Current and Future Management of Patients with Non-Hodgkin Lymphoma Faculty: Andrew M Evens, DO, MSc | Rutgers Biomedical and Health Sciences, Rutgers University | New Brunswick, New Jersey, USA This CME activity is provided by Research To Practice. This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Lilly, Novartis and TG Therapeutics Inc. | Go To Session |